Molecular staging of non-small-cell lung cancer

Yuhchyau Chen, David R Gandara

Research output: Chapter in Book/Report/Conference proceedingChapter

Abstract

Staging of non-small-cell lung cancer (NSCLC) is currently evolving. The conventional TNM system was first proposed in 1946 by Denoix and is an anatomically structured system [1]. It provides information about the size and local extension of the primary tumor (T stage), the regional lymph node metastasis (N stage), and distant hematogenous cancer spread (M stage). The TNM staging system also groups tumors of various TNM stage into subgroups I, II, III, and IV. Such division not only provides prognostic information, but also directs therapeutic decisions for tumors of different grouping categories. TNM staging was adapted by the American Joint committee for Cancer Staging (AJCC) in 1974 [2], and has been through further revisions in 1986 [3] and 1997 [4]. The staging is based on clinical information including physical examination findings, endoscopic examination findings, histologic examination of biopsy specimens, and imaging information from computed tomography (CT) scans, magnetic resonance imaging (MRI) scans, bone scans, and in the recent years, positron emission tomography (PET) scans.

Original languageEnglish (US)
Title of host publicationTumors of the Chest: Biology, Diagnosis and Management
PublisherSpringer Berlin Heidelberg
Pages159-176
Number of pages18
ISBN (Print)6293603618, 9783540310396
DOIs
StatePublished - 2006

Fingerprint

Non-Small Cell Lung Carcinoma
Neoplasm Staging
Neoplasms
Positron-Emission Tomography
Physical Examination
Lymph Nodes
Tomography
Magnetic Resonance Imaging
Neoplasm Metastasis
Biopsy
Bone and Bones
Therapeutics

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Chen, Y., & Gandara, D. R. (2006). Molecular staging of non-small-cell lung cancer. In Tumors of the Chest: Biology, Diagnosis and Management (pp. 159-176). Springer Berlin Heidelberg. https://doi.org/10.1007/3-540-31040-1_13

Molecular staging of non-small-cell lung cancer. / Chen, Yuhchyau; Gandara, David R.

Tumors of the Chest: Biology, Diagnosis and Management. Springer Berlin Heidelberg, 2006. p. 159-176.

Research output: Chapter in Book/Report/Conference proceedingChapter

Chen, Y & Gandara, DR 2006, Molecular staging of non-small-cell lung cancer. in Tumors of the Chest: Biology, Diagnosis and Management. Springer Berlin Heidelberg, pp. 159-176. https://doi.org/10.1007/3-540-31040-1_13
Chen Y, Gandara DR. Molecular staging of non-small-cell lung cancer. In Tumors of the Chest: Biology, Diagnosis and Management. Springer Berlin Heidelberg. 2006. p. 159-176 https://doi.org/10.1007/3-540-31040-1_13
Chen, Yuhchyau ; Gandara, David R. / Molecular staging of non-small-cell lung cancer. Tumors of the Chest: Biology, Diagnosis and Management. Springer Berlin Heidelberg, 2006. pp. 159-176
@inbook{6249a5d1c23343f8a744c0ce71762c78,
title = "Molecular staging of non-small-cell lung cancer",
abstract = "Staging of non-small-cell lung cancer (NSCLC) is currently evolving. The conventional TNM system was first proposed in 1946 by Denoix and is an anatomically structured system [1]. It provides information about the size and local extension of the primary tumor (T stage), the regional lymph node metastasis (N stage), and distant hematogenous cancer spread (M stage). The TNM staging system also groups tumors of various TNM stage into subgroups I, II, III, and IV. Such division not only provides prognostic information, but also directs therapeutic decisions for tumors of different grouping categories. TNM staging was adapted by the American Joint committee for Cancer Staging (AJCC) in 1974 [2], and has been through further revisions in 1986 [3] and 1997 [4]. The staging is based on clinical information including physical examination findings, endoscopic examination findings, histologic examination of biopsy specimens, and imaging information from computed tomography (CT) scans, magnetic resonance imaging (MRI) scans, bone scans, and in the recent years, positron emission tomography (PET) scans.",
author = "Yuhchyau Chen and Gandara, {David R}",
year = "2006",
doi = "10.1007/3-540-31040-1_13",
language = "English (US)",
isbn = "6293603618",
pages = "159--176",
booktitle = "Tumors of the Chest: Biology, Diagnosis and Management",
publisher = "Springer Berlin Heidelberg",

}

TY - CHAP

T1 - Molecular staging of non-small-cell lung cancer

AU - Chen, Yuhchyau

AU - Gandara, David R

PY - 2006

Y1 - 2006

N2 - Staging of non-small-cell lung cancer (NSCLC) is currently evolving. The conventional TNM system was first proposed in 1946 by Denoix and is an anatomically structured system [1]. It provides information about the size and local extension of the primary tumor (T stage), the regional lymph node metastasis (N stage), and distant hematogenous cancer spread (M stage). The TNM staging system also groups tumors of various TNM stage into subgroups I, II, III, and IV. Such division not only provides prognostic information, but also directs therapeutic decisions for tumors of different grouping categories. TNM staging was adapted by the American Joint committee for Cancer Staging (AJCC) in 1974 [2], and has been through further revisions in 1986 [3] and 1997 [4]. The staging is based on clinical information including physical examination findings, endoscopic examination findings, histologic examination of biopsy specimens, and imaging information from computed tomography (CT) scans, magnetic resonance imaging (MRI) scans, bone scans, and in the recent years, positron emission tomography (PET) scans.

AB - Staging of non-small-cell lung cancer (NSCLC) is currently evolving. The conventional TNM system was first proposed in 1946 by Denoix and is an anatomically structured system [1]. It provides information about the size and local extension of the primary tumor (T stage), the regional lymph node metastasis (N stage), and distant hematogenous cancer spread (M stage). The TNM staging system also groups tumors of various TNM stage into subgroups I, II, III, and IV. Such division not only provides prognostic information, but also directs therapeutic decisions for tumors of different grouping categories. TNM staging was adapted by the American Joint committee for Cancer Staging (AJCC) in 1974 [2], and has been through further revisions in 1986 [3] and 1997 [4]. The staging is based on clinical information including physical examination findings, endoscopic examination findings, histologic examination of biopsy specimens, and imaging information from computed tomography (CT) scans, magnetic resonance imaging (MRI) scans, bone scans, and in the recent years, positron emission tomography (PET) scans.

UR - http://www.scopus.com/inward/record.url?scp=84892793826&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84892793826&partnerID=8YFLogxK

U2 - 10.1007/3-540-31040-1_13

DO - 10.1007/3-540-31040-1_13

M3 - Chapter

AN - SCOPUS:84892793826

SN - 6293603618

SN - 9783540310396

SP - 159

EP - 176

BT - Tumors of the Chest: Biology, Diagnosis and Management

PB - Springer Berlin Heidelberg

ER -